In this episode presented by Slone Partners, Leslie Loveless, Co-CEO and Managing Partner discusses how hiring and the building of executive teams has responded to the current biotech environment.
How Biotech Funding is Changing Executive Search and Hiring Processes Read More »
While most BioSpace LinkedIn poll respondents believe the job market won’t improve until at least 2027, two industry experts are optimistic a turnaround could start sooner. They discuss early signals of recovery and challenges that remain.
When, Not If: Job Market Should Start Turning Around in Next Year or So, Experts Say Read More »
Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 combined jobs hit just 13% of that target in 2024. Ten awardees had reported layoffs last year, including Charles River Laboratories and Moderna.
21 Companies Miss Massachusetts Hiring Targets, Affecting Hundreds of Jobs Read More »
One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth disorder.
FDA Action Alert: BMS, Bayer, Arrowhead and More Read More »
The ruling removes a barrier to a deal the FTC claims will eliminate competition in the outsourced hydrophilic coatings market.
Judge denies FTC’s bid to block $627M Surmodics buyout Read More »
Major payers with a presence in the ACA, Medicare or Medicaid posted an average operating margin of -1.4% in the third quarter. The market “continues to be challenging,” complicating margin recovery plans, one expert said.
Health insurers in government programs can’t seem to turn a profit Read More »
The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of the “lingering uncertainties” surrounding the FDA, wrote one industry analyst.
Richard Pazdur, longtime FDA oncology leader, to head agency’s main drug office Read More »
After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
Biohaven Seeks $150 Million From Wall Street Following FDA Rejection Read More »
The company also posted weaker third-quarter results, but CEO David Fischel said orders for the new GenesisX system, when fully launched, would outpace the rate for an older model.
Stereotaxis nets FDA clearance for redesigned surgical robot Read More »
In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year of transformation and renewed momentum for life sciences.
Five Trends That Got Everyone Talking in Pharma and Biotech This Year Read More »
